header logo image


Page 456«..1020..455456457458..470480..»

7 Foods That Can Improve Your Vision And Keep Eye Diseases At Bay – News18

August 12th, 2020 8:44 pm

Your eyes deserve all the care in the world because if you get an eye disease, the world would not only be less interesting but also difficult to live in. A balanced diet and a healthy lifestyle are very important to maintain perfect vision. The deficiency of some nutrients, like vitamins A, C and E, omega-3 fatty acids, minerals like zinc, and antioxidants like lutein and zeaxanthin from your diet can lead to a number of eye diseases in the long run.

So, if you want to avoid everything from dry eyes and night blindness to cataracts and glaucomas, including foods that improve vision in your diet is very important. The best part, according to the American Academy of Ophthalmology (AAO), is that foods that are good for your eyes are also brilliant for your heart. So, include the following seven foods in your diet to improve your eye health:

1. Green leafy vegetables:Green veggies like spinach, kale, lettuce and collard arent just rich in dietary fibre and vitamin C but are also chock full of antioxidants like lutein and zeaxanthin.

2. Carrots:Vitamin A plays a vital role in maintaining vision because it is a component of a protein, rhodopsin, which helps your eyes absorb light. Carrots are also full of beta carotene, which is also essential for eye health.

3. Fish:Oily fish like tuna, salmon, mackerel, anchovies, sardines and trout are not only packed with lean proteins but also have high amounts of omega-3 fatty acids which are highly beneficial for your eyes.

4. Nuts and seeds:Vitamins, minerals, omega-3 fatty acids, antioxidants, phytochemicals - is there anything nuts and seeds have which isnt great for your eyes? Go on and include almonds, walnuts, chia seeds, sesame seeds and peanuts into your daily diet.

5. Citrus fruits:Fruits like oranges, lemons, cantaloupes, grapefruits are full of vitamin C, which is amazing for your eyes. Apart from that, these citrus fruits also pack other vitamins, essential minerals and antioxidants.

6. Eggs:There might be a lot of controversy surrounding the whole egg, but you should know that eggs are packed with healthy fats, vitamins, minerals, omega-3 fatty acids, antioxidants and proteins - and all of these are great for your eyes. So, forget what youve heard about yolks being unhealthy and eat whole eggs (in moderation, of course) for eye health.

7. Legumes:Legumes, also known as dal in India, are great sources of plant-based proteins, and also have high levels of vitamin E and omega-3 fatty acids, which are great for your vision. Make sure you have a bowl of dal every day.

For more information, read our article onHow to improve eyesight.

Health articles on News18 are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.

The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor News18 is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.

Read the original here:
7 Foods That Can Improve Your Vision And Keep Eye Diseases At Bay - News18

Read More...

eSight Wins CE Mark for Wearable to Enhance Vision – Medical Device and Diagnostics Industry

August 12th, 2020 8:44 pm

eSight has won CE mark for a wearable assistive technology that can enhance vision for people living with low vision and legal blindness.

The device works for those living with visual acuities from 20/60 to 20/1400 (perfect vision is 20/20) caused by more than 20 different eye conditions including macular degeneration, diabetic retinopathy and Stargardt's disease.

Macular degeneration is a global phenomenon that millions of people suffer from, Robert Vaters, esights president and CEO, told MD+DI. We have the best product to help people navigate it.

The Toronto-based companys technology works by combining a camera and lens technology with advanced sensors and algorithms to maximize the quality of information sent to the brain, which in turn dramatically augments sight.

Wireless with built-in vision controls, the eSight 4 headset features an ergonomically designed halo band with a rechargeable battery that can be replaced within seconds for all-day comfort and use. eSight 4 is also cloud-based, so wearers are provided with easy and instant access to the latest features and invite loved ones and eSight support members to see what they are seeing and help manage their eSight experience.

Other key features of the device include advanced controls, allowing the user to control their vision with 24x zoom and a bioptic tilt to maintain use of natural peripheral vision, and a new Apple and Android mobile apps that make it easier for people with low vision to see their smartphone screen in detail and watch content.

Because of the impact of COVID-19, eSight had to forego a traditional launch of the product and instead move toward a virtual one.

Traditionally, we would be present at conferences where there are physical people, he said. We would also have launch events in localities like for example Florida. Its been a thing that everybody in every kind of business has had to adjust to. I think weve done quite a really good job because we were already in the process before COVID of doing demos online and working with our potential customers through the product remotely.

Visit link:
eSight Wins CE Mark for Wearable to Enhance Vision - Medical Device and Diagnostics Industry

Read More...

Vision Care Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and Forecast to 2027 – Chelanpress

August 12th, 2020 8:44 pm

What is Vision Care?

Vision care is the care and treatment of eyes, eyesight conditions, and vision. The exploding use of electronic devices for everyday functioning has also been related to eye disorders. In recent years, the use of technology has particularly increased among children. Studies suggest excessive use of electronic devices could lead to eye disorders. This indirectly is stoking demand for vision care products.

The vision care market is driving due to the rising geriatric population more susceptible to eye diseases and technological advances in eye care devices. Moreover, the raise awareness for eye health and to address vision-related problems is also serving to boost the vision care market.

Request Sample Copy of Vision Care Market at: https://www.theinsightpartners.com/sample/TIPRE00011953/

The research provides answers to the following key questions:

Vision Care Industry Report focuses on Market Influence Factors, Growth Drivers, Restraints, Trends and Opportunities so that Market Players can face any challenges and take advantage of Lucrative Prospects available in the Global Vision Care market.

The Vision Care Market Analysis to 2027 is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of vision care market with detailed market segmentation by product type and distribution channel. The vision care market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in vision care market and offers key trends and opportunities in the market.

The Emerging Players in the Vision Care Market includes Alcon, Bausch and Lomb, Carl Zeiss, CooperVision, Essilor, Johnson & Johnson, LUXOTTICA GROUP, Rodenstock, Safilo Group, ZEISS, etc.

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Medical Device, Pharmaceutical, Healthcare and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Vision Care Market globally. This report on Vision Care Market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Vision Care industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Vision Care market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Vision Care market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Vision Care Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00011953/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

More here:
Vision Care Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and Forecast to 2027 - Chelanpress

Read More...

Do dogs really see in just black and white? – North Platte Telegraph

August 12th, 2020 8:44 pm

Don't worry that your dog's world is visually drab.Kevin Short/EyeEm via Getty Images

Curious Kids is a series for children of all ages. If you have a question youd like an expert to answer, send it to curiouskidsus@theconversation.com.

Do dogs really see in just black and white? Oscar V., age 9, Somerville, Massachusetts

Dogs definitely see the world differently than people do, but its a myth that their view is just black, white and grim shades of gray.

While most people see a full spectrum of colors from red to violet, dogs lack some of the light receptors in their eyes that allow human beings to see certain colors, particularly in the red and green range. But canines can still see yellow and blue.

Different wavelengths of light register as different colors in an animals visual system. Top is the human view; bottom is a dogs eye view. Top: iStock/Getty Images Plus via Getty Images. Bottom: As processed by Andrs Pter's Dog Vision Image Processing Tool

What you see as red or orange, to a dog may just be another shade of tan. To my dog, Sparky, a bright orange ball lying in the green grass may look like a tan ball in another shade of tan grass. But his bright blue ball will look similar to both of us. An online image processing tool lets you see for yourself what a particular picture looks like to your pet.

Animals cant use spoken language to describe what they see, but researchers easily trained dogs to touch a lit-up color disc with their nose to get a treat. Then they trained the dogs to touch a disc that was a different color than some others. When the well-trained dogs couldnt figure out which disc to press, the scientists knew that they couldnt see the differences in color. These experiments showed that dogs could see only yellow and blue.

In the back of our eyeballs, human beings retinas contain three types of special cone-shaped cells that are responsible for all the colors we can see. When scientists used a technique called electroretinography to measure the way dogs eyes react to light, they found that canines have fewer kinds of these cone cells. Compared to peoples three kinds, dogs only have two types of cone receptors.

Light travels to the back of the eyeball, where it registers with rod and cone cells that send visual signals on to the brain. iStock/Getty Images Plus via Getty Images

Not only can dogs see fewer colors than we do, they probably dont see as clearly as we do either. Tests show that both the structure and function of the dog eye leads them to see things at a distance as more blurry. While we think of perfect vision in humans as being 20/20, typical vision in dogs is probably closer to 20/75. This means that what a person with normal vision could see from 75 feet away, a dog would need to be just 20 feet away to see as clearly. Since dogs dont read the newspaper, their visual acuity probably doesnt interfere with their way of life.

Theres likely a lot of difference in visual ability between breeds. Over the years, breeders have selected sight-hunting dogs like greyhounds to have better vision than dogs like bulldogs.

But thats not the end of the story. While people have a tough time seeing clearly in dim light, scientists believe dogs can probably see as well at dusk or dawn as they can in the bright middle of the day. This is because compared to humans, dog retinas have a higher percentage and type of another kind of visual receptor. Called rod cells because of their shape, they function better in low light than cone cells do.

Dogs also have a reflective tissue layer at the back of their eyes that helps them see in less light. This mirror-like tapetum lucidum collects and concentrates the available light to help them see when its dark. The tapetum lucidum is what gives dogs and other mammals that glowing eye reflection when caught in your headlights at night or when you try to take a flash photo.

Dogs share their type of vision with many other animals, including cats and foxes. Scientists think its important for these hunters to be able to detect the motion of their nocturnal prey, and thats why their vision evolved in this way. As many mammals developed the ability to forage and hunt in twilight or dark conditions, they gave up the ability to see the variety of colors that most birds, reptiles and primates have. People didnt evolve to be active all night, so we kept the color vision and better visual acuity.

Before you feel sorry that dogs arent able to see all the colors of the rainbow, keep in mind that some of their other senses are much more developed than yours. They can hear higher-pitched sounds from farther away, and their noses are much more powerful.

Even though Sparky might not be able to easily see that orange toy in the grass, he can certainly smell it and find it easily when he wants to.

Hello, curious kids! Do you have a question youd like an expert to answer? Ask an adult to send your question to CuriousKidsUS@theconversation.com. Please tell us your name, age and the city where you live.

And since curiosity has no age limit adults, let us know what youre wondering, too. We wont be able to answer every question, but we will do our best.

Nancy Dreschel does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

This article is republished fromThe Conversationunder a Creative Commons license.

Go here to see the original:
Do dogs really see in just black and white? - North Platte Telegraph

Read More...

Scientists Gene-Hack Cotton Plants to Make Them Every Color of the Rainbow – Singularity Hub

August 12th, 2020 8:43 pm

Imagine this: Youre on a drive through cotton country. The suns out, tops down. Its a beautiful, totally normal day. Only, what was once a sea of white puff balls has transformed into a multi-hued swirl. Lines of deep purple, bright yellow, midnight blue. All the colors in the rainbowand your t-shirt drawer, as it so happens.

Today, youd do well to check your water. But in the future, colorful cotton could be the normAustralian scientists are having early success genetically modifying the crop to make it multicolored. And although color is their latest project, theyre also working to make synthetic-like, stretchy cotton.

The team hopes their new cotton plants might eventually be grown widely and made into clothes, helping to displace the toxic dyes and synthetic materials used by the fashion industry.

And thats a worthy cause.

The numbers are hard to pin down exactly, but theres little doubt that how we make clothes could be more environmentally friendly. In textile manufacturing, which often takes place in developing countries, those harmful dyes can cause health problems for workers and do more damage as toxic runoff. Also, the life cycle of clothing isnt as long as it once was. While some items will get a second life by way of a thrift store, it all eventually makes its way to a landfill, where the synthetic materials in many clothes can take centuries to break down.

The holy grail then? Non-toxic, compostable clothing. And while its still early, the tools of synthetic biology and genetic engineering may well prove a big part of the solution.

To be totally clear, cotton doesnt only grow in one color. (This was news to me, so maybe it is to you too.) Some varieties, dating back millennia, are naturally dark chocolate, light brown, and even mauve. These were traditionally used in handwoven textiles, but with the Industrial Revolution, naturally pigmented cotton gave way to white cotton because it had longer, higher quality fibers, you could dye it any color on the cheap, and it didnt require specialized equipment or methods to harvest.

In the 80s and 90s, as people became more environmentally conscious, there was a revival of naturally pigmented cotton. You could make clothes from it without dye and suppliers were often small, organic farmers. There was even work to make it amenable to industrial looms. Sally Fox, for example, developed varieties with longer fibers in an array of colors.

Still, naturally colored cotton is generally more expensive to produce, the color range is limited, and the fiber quality is lower than white cotton.

Enter genetic engineering.

As far back as 1993, people were talking about adding color genes to cotton. Two biotech companies, Agracetus and Calgene, had plans to splice in genes from the indigo plant to make cotton for blue jeans. Of course it will work, Ken Barton, vice-president of research and development at Agracetus, said at the time. Give a scientist enough time and money and he can do anything. Of course, were still dying jeans 27 years laterbut maybe the time has come.

As with all things in the realm of biology, the devils in the details, but our tools for manipulating nature have advanced in the last few decades too.

An array of tiny, brilliantly colored buds of cotton tissue are sitting in a few dozen petri dishes in a Canberra greenhouse (check out images here). In one dish, the cotton is raspberry red; in the other its yellow like a mango. The tissue, which carries genes for color spliced in by scientists at Australias scientific research agency, CSIRO, is only the first step, but its a promising one. In the next few months, the team, led by senior research scientist, Colleen MacMillan, will coax the tissue into full-grown cotton plants.

If all goes to plan, the cotton fiber will be just as colorful as the petri dish tissue. The team points to splotches of color on leaves of tobacco plants carrying the cotton genes as likely evidence theyll take. If the leaves of the cotton plants are similarly colored, the cotton fiber will be too.

Weve seen some really beautiful bright yellows, sort of golden-orangey colors, through to some really deep purple, Filomena Pettolino, a scientist on MacMillans team, told Australias ABC News. The team is also working on black cotton, which would be a significant achievementblack dyes are notoriously the nastiest, most toxic of the lot. And the less dye the better.

Though theyre favored for speed and quality, synthetic dyes can include formaldehyde and heavy metals which stain the skin and cause cancer. That early-90s dream to make jeans with blue cotton? Its just as relevant today. In the Chinese province of Xintang, where 300 million pairs of jeans are dyed each year, the toxic runoff flows into rivers by the gallon.

In parallel to their work in multicolored cotton, the team has a longer-term project to make synthetic-like cotton. Synthetics like polyester and nylon make their way into the environment from washing machineswhich pull off and flush microfibers from the fabricand of course, they also line landfills. The team is screening thousands of plants, hunting for proteins with just the right properties: stretchy, wrinkle-free, and maybe even waterproof.

Were looking into the structure of cotton cell walls and harnessing the latest tools in synthetic biology to develop the next generation cotton fiber, CSIRO scientist Dr Madeline Mitchell said. Weve got a whole bunch of different cotton plants growing; some with really long thin fibers, others like the one we call Shaun the Sheep, with short, woolly fibers.

It remains to be seen whether this next-gen cotton can keep up with fashions insatiable demand for new huesthough black is never out of styleif it can yield as much as a standard cotton plant, and what it will cost farmers.

First, though, this team (or another) will need to prove they can grow the stuff and produce seeds at scale. But if it works, you or someone you know may one day rock a pair of fully compostable, bright purple yoga pants of gene-hacked cotton.

Image credit: Crystal de Passill-Chabot / Unsplash

See original here:
Scientists Gene-Hack Cotton Plants to Make Them Every Color of the Rainbow - Singularity Hub

Read More...

Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property from…

August 12th, 2020 8:43 pm

Transfer of Caribous novel microbial IP will enable new therapeutic opportunities for Novome

License to CRISPR-Cas9 intellectual property controlled by Caribou will accelerate the development of preclinical candidates built on Novomes proprietary synthetic biology platform

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced that it has taken assignment to certain microbial intellectual property, and has non-exclusively licensed foundational CRISPR-Cas9 intellectual property controlled by Caribou Biosciences, a leading CRISPR genome editing company, to expand its therapeutic pipeline and platform capabilities.

This is an important milestone for Novome that should unlock new therapeutic avenues while we accelerate the pace of preclinical development at the company. The ability to leverage the efficient and flexible CRISPR-Cas9 system will allow us to rapidly iterate on GEMM strain designs to generate the most promising therapeutic candidates, said Blake Wise, Chief Executive Officer of Novome. Additionally, we are excited to leverage the progress made by Caribous microbial group and advance this promising science.

Under the terms of an assignment agreement, Novome acquired ownership of certain intellectual property and preclinical projects related to undisclosed therapeutic areas. Additionally, pursuant to a license agreement, Novome received a non-exclusive license to foundational CRISPR-Cas9 intellectual property controlled by Caribou for genetic modification of bacterial species for administration as therapeutics in humans. Terms of the agreements have not been disclosed. Novome will have full control of development, manufacturing, and commercialization of any product candidates covered by either the assignment agreement or the license agreement.

Novome developed the first platform for controlled and robust colonization of the human gut with engineered therapeutic bacteria, its Genetically Engineered Microbial Medicines (GEMMs) platform. The Company is focused on advancing its lead hyperoxaluria program through Phase 1 clinical proof-of-concept work and expanding its platform and pipeline to address additional disease indications.

Novome was founded in 2016 by scientists from Stanford University and the University of California, Berkeley, based on research performed in the laboratory of Scientific Co-founder Dr. Justin Sonnenburg, Associate Professor, Stanford University. The founding team, Drs. Will DeLoache, Weston Whitaker, Zachary Russ, and Liz Shepherd, combines deep expertise in synthetic biology and the study of the gut microbiota. Their work has led to numerous peer-reviewed scientific publications, as well as the filing of a portfolio of patents, both developed at Novome and licensed exclusively from Stanford.

About Genetically Engineered Microbial MedicinesGenetically Engineered Microbial Medicines (GEMMs) are proprietary bacterial strains designed to colonize the gut at a controllable abundance and express therapeutic transgenes at clinically meaningful levels. Colonization is maintained using a daily dose of prebiotic polysaccharide that GEMMs are engineered to depend upon for their survival.

About NovomeNovome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

Source: Novome Biotechnologies, Inc.

Go here to see the original:
Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property from...

Read More...

Baseceuticals Offers Oncolytic Virus Services to Accelerate the Development in Gene Therapy – Press Release – Digital Journal

August 12th, 2020 8:43 pm

Baseceuticals recently announced its release of the oncolytic virus service aiming to accelerate the development of gene therapy.

New York, USA - August 12, 2020 - Baseceuticals, the major division of Creative Biogene, mainly targets on gene therapy to provide various services for researchers and institutes to develop new drugs, including genetic modification, gene delivery systems and preclinical trials, recently announced its release of the oncolytic virus service aiming to accelerate the development of gene therapy.

As a global leader in the field of gene therapy, Baseceuticals provides high-quality oncolytic virus services based on an excellent and mature platform. Relying on the most advanced technology and the most advanced equipment, the experienced technical team has successfully completed many oncolytic virus projects, including oncolytic virus construction, engineering and verification. After communicating and analyzing the specific situation, Baseceuticals can propose the best strategy for the project to meet specific needs.

Oncolytic viruses have been used for treatment in clinical trials, and an oncolytic virus product T-VEC has been approved by the FDA. Oncolytic virus therapy has been recognized as a promising and effective cancer treatment method. Compared with radiotherapy and chemotherapy, it is easier to destroy tumor cells.

Oncolytic viruses (OV) are a group of tumor-killing viruses with replication ability that can effectively multiply in cancer cells without damaging healthy cells. According to development, oncolytic viruses can be divided into two categories, namely natural viruses and genetically modified viruses. Among them, natural viruses include broad and natural variants of weak viruses. The main advantage of oncolytic viruses is that they can quickly produce virus particles and genetically engineer other genes to enhance anti-tumor immunity, increase tumor cell sensitivity and improve patient safety. Oncolytic virus services provided by Baseceuticals include oncolytic virus construction, oncolytic virus engineering, oncolytic virus verification, and development of disease-specific oncolytic virus therapy.

Highlights of Oncolytic Virus Service in Baseceuticals:

1. Years of rich experience in oncolytic virus services2. Leading equipment and first-class technology3. Fast turnaround time and reliable results4. A variety of oncolytic viruses are available5. Reasonable price and quality service6. Customize services to meet specific requirements through feasible suggestions

"Baseceuticals provides high-quality oncolytic virus services, our technical research team specializes in efficient systems and procedures in projects related to oncolytic viruses," said Marcia Brady, she also claimed, "Our oncolytic virus service starts with free communication and then feasible suggestions to meet your specific needs. We are confident to provide the best oncolytic virus service at an affordable price and reliable results."

About Baseceuticals

With years of experience and advanced technologies, Baseceuticals provides worldwide customers with innovative products and services to greatly enhance the clinical application and drug launches. As a division of Creative Biogene, Baseceuticals has become a well-recognized industry leader to support scientists from research institutes, government, pharmaceutical companies, diagnosis industries and testing laboratories.

Media ContactCompany Name: Creative BiogeneContact Person: Marcia BradyEmail: Send EmailPhone: 1-631-619-7922Country: United StatesWebsite: https://baseceuticals.creative-biogene.com

Continue reading here:
Baseceuticals Offers Oncolytic Virus Services to Accelerate the Development in Gene Therapy - Press Release - Digital Journal

Read More...

Top 5 Investors That You Should Certainly Know About in 2020 – Kev’s Best

August 12th, 2020 8:43 pm

2020 will be remembered as the year the COVID-19 pandemic brought the world to a standstill, as national lockdowns were instituted across the globe. As sectors of the global economy have endured lockdown, curfews and structural changes to combat the virus, global businesses have been forced to adapt and overcome unforeseen challenges and circumstances.

Despite such fundamental changes, some of the brightest minds in the investment world have carried on with their innovations, whether it be in fintech, space exploration, biomedical research or other sectors.

After extensive research and evaluation, here is our list outlining the top 5 investors making the biggest impact in 2020:

Andreessen Horowitz (a16z) was founded in 2009 by Marc Andreessen and Ben Horowitz. Based in Silicon Valley, the company has been massively successful under the leadership of Marc and Ben. Ben has overseen investment across several industry sectors, including crypto, fintech, healthcare and consumer goods. With respect to crypto, a16z has made a large bet on Ripple, which with the sole exceptions of Bitcoin and Ethereum, is the most valuable crypto by market capitalization. Bens firm currently manages over $12 billion in assets and continues to grow rapidly. As if that wasnt enough, Ben is now a New York Times best-selling author. 2020 has not slowed Ben or a16z down, and Ben continues to be one of the leading investors in the world.

Peter Thiel is number 2 on the list, and he is known as a prolific entrepreneur and venture capitalist with an estimated worth of $2.3 billion USD. He is a co-founder of PayPal, and also took the company public after leading it as CEO. He also serves as chairman of Palantir Technologies which, alongside PayPal and Facebook, is rumoured to be the main source of his current wealth. His is a partner of Silicon Valley venture capital firm Founders Fund and has a passion for investing in startups that he sees potential in. He is also a New York Times bestselling author for his books How to Build the Future and Zero to One: Notes on Startups.

Coming in at number 3 on our list is Dylan Taylor, who is an active pioneer in the super-hot industry of space exploration. Taylor is regarded as a super angel investor in the NewSpace industry but more recently, he has turned his attention to controlling interest investments. Taylor is the CEO and Chairman of Voyager Space Holdings, which is an international corporation focused on acquiring and integrating space exploration enterprises on a global level. Earlier in 2020, Dylan was awarded the space industrys top honour by the Commercial Spaceflight Federation for his contributions to business and finance.

Number 4 on our list, Laura Deming is a New Zealand born venture capitalist who has focused her investments on biological research with the aim of reversing, or at least reducing, the effects of aging. At a very young age, she showed interest in the possibilities of genetic engineering to extend lifespans, and she was accepted into MIT at the age of 14 to study physics. She dropped out of MIT after receiving a $100,000 investment from Peter Thiel (number 2 on our list) to start her own venture capital firm, The Longevity Fund. As the name implies, The Longevity Fund is focused on investments in aging and life extension, and as its founder, Laura is considered a leader in the anti-aging field and has been a keynote speaker on the topic.

Lee Fixel is an American venture capitalist who has had a range of outstanding successes. He joined Tiger Global in March 2006 and established himself as one of the pre-eminent investors in software and internet-based companies. Fixel has backed companies like Flipkart and Peloton, both of which have been incredibly successful and have achieved unicorn status. After leaving Tiger Global in 2019, Fixel has set his sights on a new target, having spent much of his recent time away from the public eye. Whether this is because of COVID-19 or personal reasons remains to be seen; however, Fixel has announced the formation of a multi-stage venture capital firm called Addition. The VC firm has already raised more than $1.3 billion and is backing well-known companies like Fauna.

Cameron Dickerson is a seasoned journalist with nearly 10 years experience. While studying journalism at the University of Missouri, Cameron found a passion for finding engaging stories. As a contributor to Kevs Best, Cameron mostly covers state and national developments.

Read the rest here:
Top 5 Investors That You Should Certainly Know About in 2020 - Kev's Best

Read More...

Letter: A hardy group of concerned Islanders remain at the forefront against herbicides – Manitoulin Expositor

August 12th, 2020 8:43 pm

No rest until the government bans the use of glyphosate in all its forms

To the Expositor:

Islanders rightly oppose use of glyphosate-based herbicides, but this is a world-wide problem.

Over the last two years, a small group of concerned Islanders have often felt like mosquitoes trying to sting a corporate elephant. This powerful corporationoriginally Monsantonow part of an even larger corporationBayeris worth around $100 billion!

Originally, their focus was local, urgent and modest in scope. Some Island residents (Zak Nichols, Petra Wall, myself and Pat Hess) had seen statutory notices published in our local media informing the Manitoulin public that Hydro One was planning to spray a herbicide (glyphosate-based Garlon) in sections of its rights of ways on the Island, and they were opposed to this.

They approached several Island municipal councils to get their support for trying to stop this. That support was eventually given, though not without some resistance.

In parallel, the group set up petitions to approach the Ontario governments Minister of Environment asking for the legislation governing pesticide use (Pesticides Act) to be changed. Between the two, they collected well over 1,000 signatures from Islanders who shared their concern about the use of glyphosates. MPP Michael Mantha presented the petitions to the Ontario legislature and to the appropriate minister. Unfortunately, all the group got back were perfunctory replies.

The Expositor and Recorder have done a wonderful job in the past reporting on the groups efforts to highlight the questionable use of pesticides on the Island.

Glyphosate-based products have been around for several decades. They became controversial in the early 2000s when Monsanto packaged glyphosate for residential use as Roundup targeted for spraying dandelions on home lawns and driveways (generally referred to as cosmetic use).

Local municipalities responded to citizens of the day with local bylaws that covered the full spectrum of limitations and bans. By 2009, this had become such an irritant to the government that the then-minister, John Gerretsen, enacted the Cosmetic Pesticides Act which took away all authority from the municipal level to enact further bylaws, and rendered all those that existed as retroactively inoperative, leaving municipalities with few tools in their toolbox to respond to citizens concerns.

Zak Nichols and myself got hundreds of signatures on a petition a couple of years ago. Petra Wall got a similar number so Manitoulin residents and other Ontarians agree there are concerns. Mike Mantha carried the petitions to Queens Park and sent them to the then Minister of the Environment, but since then there have been three changes of minister (maybe fourits getting hard to keep count). Several Manitoulin municipalities were formally supportive of our efforts but couldnt pass bylaws on this because the Ontario government took away their authority to do that.

So, what has happened since then? Well, the pesticides in question, glyphosates, found in products like Garlon and Roundup, has been proven to be cancer-causing. The manufacturer, Bayer-Monsanto, has been losing court cases in the US so fast it is now contemplating make a $12 billion offer to all litigants so it can get on with the rest of its business.

Meanwhile, many other jurisdictions have begun to phase out use of glyphosates. The latest is Mexico, which announced in June that it will be ordering the phasing out of glyphosate use by 2024. Canada currently appears to be ignoring what is happening in the rest of the world. If anything, the current Ontario government appears to be loosening the rules for use of pesticides generally.

So, what is the group looking for now? First, they would like the government of Ontario (and ideally the government of Canada) to ban use of glyphosate in all its forms. That would address their immediate concern which is the use of this poisonous product for vegetation management alongside roads by the utility companies and the contractors they use. Some of them are frankly careless in the way they use the product and several Islanders have reported incidents they have observed where the spraying is taking place. There are specialized contractors on the Island. We understand that they are conscientious and use great care, but they are using glyphosate products (Roundup) and should prepare to change. Second, they want authority to manage these kinds of threats to be passed back to the municipalities which are answerable to their populations. As climate change continues, it will have different impacts in local zones and it is vital that local authorities have all the tools they need to manage problems that could occur.

And the mosquito and the elephant? They have had experiences of both government (specifically environment) and corporate entities (Hydro One) increasingly ignore them even though what they were asking for was reasonable to they hope glyphosates will be banned here sooner or later. Hydro One has been implying recently that they are now a private sector entity and not subject to Access to Information requirements. Well, these mosquitoes will not be brushed off and will find ways to penetrate the hides.

Of course, the cosmetic use of glyphosate products is just the tiniest tip of the smallest market for this pesticide. For the real part of glyphosate use, you have to look at agriculture (incidentally one of the four areas of exception in the Pesticides Act following enactment of the Cosmetic Pesticides Act).

Worldwide, glyphosate based products total up to an estimated 8.6 billion kilograms annually (the figures for Canada not available at time of going to press). Not bad for a chemical which in its early days couldnt find a use!

But for a general herbicide that kills on a broad spectrum, not exactly useful in agriculture until someone in Monsanto thought now genetic engineering is well understood. If we could genetically engineer crop seeds to be resistant to glyphosate, we could have a lock on the market both coming and going so voila, along came GMO seeds and the rest is history.

Paul Darlaston

Kagawong

More:
Letter: A hardy group of concerned Islanders remain at the forefront against herbicides - Manitoulin Expositor

Read More...

CRISPR Gene-Editing Market Future Growth Analysis, Business Demand and Opportunities to 2027 | Applied StemCell, ACEA BIO, Synthego, Thermo Fisher…

August 12th, 2020 8:43 pm

Global CRISPR Gene-Editing Market report performs systematic gathering, recording and analysis of data about the issues related to the marketing of goods and services and serves the businesses with an excellent market research report. The report provides intelligent solutions to complex business challenges and commences an effortless decision-making process. The report analyses and evaluates the important industry trends, market size, market share estimates, and sales volume with which industry can speculate the strategies to increase return on investment (ROI). In the Global CRISPR Gene-Editing Market document, the statistics have been represented in the graphical format for an unambiguous understanding of facts and figures.

CRISPR gene-editing marketis rising gradually with a healthy CAGR of 23.35 % in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth.

Get a Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crispr-gene-editing-market

Key Market Players:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global CRISPR Gene-Editing Market By Therapeutic Application (Oncology, Autoimmune/Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR/Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr/Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Global CRISPR Gene-Editing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the CRISPR Gene-Editing Industry

High prevalence of cancer worldwide is driving the growth of this marketJoint ventures by biotechnical companies for the advancement of genetic engineering for the development of CRISPR worldwide can also boost the market growthExpanding the application of CRISPR technology by innovative research from the different academic organizations also enhances the market growth

High finance in research and development also acts as a driving factor in the growth of this marketProbable mistreatment of CRISPR gene editing device and CRISPR/Cas genome editing device is restricting the growth for the marketScientific and major technical challenges for the production of disease specific novel CRISPR gene editing can also hamper the market growthLack of healthcare budget in some middle-income countries restricts the market growth

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-crispr-gene-editing-market

The titled segments and sub-section of the market are illuminated below:

By Therapeutic

OncologyAutoimmune/Inflammatory

By Application

Genome EngineeringDisease ModelsFunctional GenomicsOthers

By Technology

CRISPR/Cas9Zinc Finger NucleasesOthers

By Services

Design ToolsPlasmid and VectorCas9 and g-RNADelivery System ProductsOthers

By Products

GenCrispr/Cas9 kitsGenCrispr Cas9 AntibodiesGenCrispr Cas9 EnzymesOthers

By End-Users

Biotechnology & Pharmaceutical CompaniesAcademic & Government Research InstitutesContract Research OrganizationsOthers

Top Players in the Market are:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

How will the report help new companies to plan their investments in the CRISPR Gene-Editing market?

The CRISPR Gene-Editing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-crispr-gene-editing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: CRISPR Gene-Editing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: CRISPR Gene-Editing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Link:
CRISPR Gene-Editing Market Future Growth Analysis, Business Demand and Opportunities to 2027 | Applied StemCell, ACEA BIO, Synthego, Thermo Fisher...

Read More...

Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020 – GlobeNewswire

August 12th, 2020 8:43 pm

GAITHERSBURG, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.

Conference call details are as follows:

Conference call and webcast replay:

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVXCoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in its Phase 1 portion of the Phase 1/2 clinical trial. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.

InvestorsSilvia Taylor and Erika Trahanir@novavax.com240-268-2022

MediaAmy Speakamy@speaklifescience.com617-420-2461

Visit link:
Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020 - GlobeNewswire

Read More...

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – PharmiWeb.com

August 11th, 2020 12:50 pm

Cell, Gene & Tissue-Based Therapy Developers Poised to Break Year-Over-Year Global Financing Records

WASHINGTON, D.C. August 6, 2020 The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, Innovation in the Time of COVID-19. The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

As the voice of the sector globally, ARM regularly publishes sector data reports to showcase clinical and scientific progress, as well as advancements and remaining challenges in the policy environment surrounding cell, gene and tissue-based therapies. The report also includes updated metrics on fundraising and clinical trials from more than 1,000 therapeutic developers worldwide.

Highlights from the H1 2020 Global Sector Report include:

Janet Lambert, CEO of ARM, commented: The regenerative medicine and advanced therapy sector has shown remarkable resilience in the face of many new challenges posed by COVID-19. Most importantly, were continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. ARM will continue to work with our membership and with policymakers in the second half of 2020 to further advance these transformative technologies. We are committed to bringing these life-changing therapies to patients in need.

This report is the latest in ARMs series of global regenerative medicine sector reports, providing up-to-date metrics on financings and the clinical landscape, as well as expert commentary on key trends and progress in the field. The full report is available online here, with key sector metrics and infographics available here. For more information, please visit http://www.alliancerm.org or contact Kaitlyn (Donaldson) Dupont at kdonaldson@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 360+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Visit link:
New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - PharmiWeb.com

Read More...

New Study Presents Cell-based Therapy for MN Diseases or Spinal Cord Disorders – Mirage News

August 11th, 2020 12:50 pm

The spinal cord is a bundle of nerves inside the spine that gives your body structure and support. Spinal cord injuries (SCIs) tend to be devastating and most are permanent. Recent research has shown that motor neuron obtained from skin cells could serve as potential treatments for spinal cord injuries, and thus has received considerable research attention. With this, a new door has been opened for treating not only spinal cord injuries, caused by workplace accidents and car crashes, but also Lou Gehrigs disease, known as amyotrophic lateral sclerosis or ALS.

A research team, led by Professor Jeong Beom Kim and his research team in the School of Life Sciences at UNIST has demonstrated that human fibroblasts can be converted into induced motor neurons (iMNs) by sequentially inducing two transcription factors, POU5F1(OCT4) and LHX3. The research team further investigated the therapeutic effects of iMNs for treating traumatic spinal cord injury using rodent spinal cord injury model. Their findings indicate that the sequential induction of two transcription factors is essential for generating self-renewing iMNICs more efficiently. This method not only ensures large-scale production of pure iMNs, but also facilitates the feasibility of iMNs for SCI treatment.

The spinal cord is responsible for transmitting signals from the brain to the rest of the body, and vice versa. Along with motor and sensory deficits, damage to the spinal cord can cause long-term complications, including limited mobility. Although there are many treatment options available for people with SCI, most of them have adverse side effects that impact therapy. And this is why stem cell (SC) therapies to restore functions of damaged tissues are attracting attention, recently. Among those cells constituting the spinal cord, motor neurons that involved in the regulation of muscle function have emerged as a promising candidate for the stem cell-based therapy for SCIs. Despite these encouraging advances, ethical issue of embryonic stem cells (ESCs) and tumorigenic potential of induced pluripotent stem cells (iPSCs) have impeded their translations into clinical trials.

Figure 1. The experimental scheme for the generation of induced motor neurons (iMNs) from human fibroblasts via sequential transduction of two transcription factors.

To overcome these limitations, Professor Kim and his research team established an advanced direct conversion strategy to generate iMNs from human fibroblasts in large-scale with high purity, thereby providing a cell source for the treatment of SCI. These iMNs possessed spinal cord motor neuronal identity and exhibit hallmarks of spinal MNs, such as neuromuscular junction formation capacity and electrophysiological properties in vitro. Importantly, their findings also show that transplantation of iMNs improved locomotor function in rodent SCI model without tumor formation. According to the research team, This proof-of-concept study shows that our functional iMNs can be employed to cell-based therapy as an autologous cell source. Through this, they resolved the problem of immune rejection, and thus reduce the risk of cancer.

In the study, we succeeded in generating iMNs from human fibroblasts by overexpressing POU5F1(OCT4) and LHX3, says Hyunah Lee (Combined MS/Ph.D program of Life Sciences, UNIST), the first author of the study.

Figure 2. Therapeutic effects of iMNs in rat spinal cord injury model in vivo. (A) The position of hindlimbs in control rat and iMN-transplanted rat after 8 weeks of transplantation. (B) C staining analysis of spinal cords after 8 weeks of transplantation (I; Control, J; iMN-transplanted).

The developed motor nerve cell manufacturing method has the advantage of being capable of mass production. A sufficient amount of cells is required for patient clinical treatment, but the existing direct differentiation technique has limited the number of cells that can be obtained. On the other hand, the method developed by the research team is capable of mass production because it undergoes an intermediate cell stage capable of self-renewal. After injecting the produced cells into the spinal cord injury mice, it was confirmed that the lost motor function is restored and the nerves are regenerated in the damaged spinal cord tissue.

Although further investigation on mechanism responsible for cell fate conversion may be needed, our strategy is a safer and simpler methodology that may provide new insights to develop personalized stem cell therapy and drug screening for MN diseases or spinal cord disorders, says Professor Kim. If combined with SuPine Patch, an adhesive hydrogel patches with the purpose of regenerating the damaged spinal cords, its therapeutic effects will be maximized. He adds, As the incidence of spinal cord injury is high due to industrial accidents, synergistic effects with public hospitals specializing in industrial accidents scheduled to be built in Ulsan should be expected.

This study has been jointly carried out with Professor Kims startup company, SuPine Therapeutics Inc. with the support of the Ministry of SMEs and Startups (MSS). The findings of this research have been published in the 2020 June issue of the online edition of eLife, a renowned academic journal of the European Molecular Biology Organizationl (EMBO).

Journal Reference

Hyunah Lee, Hye Yeong Lee, Byeong Eun Lee, et al., Sequentially induced motor neurons from human fibroblasts facilitate locomotor recovery in a rodent spinal cord injury model, eLife, (2020).

Continue reading here:
New Study Presents Cell-based Therapy for MN Diseases or Spinal Cord Disorders - Mirage News

Read More...

Embryos could be vulnerable to covid-19 in second week of pregnancy: Study – Livemint

August 11th, 2020 12:50 pm

LONDON :Human embryos could be susceptible to COVID-19 as early as the second week of pregnancy, if the mother gets sick, potentially affecting the chances of a successful pregnancy, according to a study.

Scientists at the UK's University of Cambridge and California Institute of Technology in the US found that genes thought to play a role in how the SARS-CoV-2 virus infects our cells have been found to be active in embryos as early as during the second week of pregnancy.

While initially recognised as causing respiratory disease, the SARS-CoV-2 virus, which causes COVID-19 disease, also affects many other organs, they said.

Advanced age and obesity are risk factors for complications but questions concerning the potential effects on foetal health and successful pregnancy for those infected with SARS-CoV-2 remain largely unanswered, according to the researchers.

In the journal Open Biology, the researchers described how they used technology to culture human embryos through the stage they normally implant in the body of the mother to look at the activity - or 'expression' - of key genes in the embryo. On the surface of the SARS-CoV-2 virus are large 'spike' proteins. Spike proteins bind to ACE2, a protein receptor found on the surface of cells in our body, the researchers explained. Both the spike protein and ACE2 are then cleaved, allowing genetic material from the virus to enter the host cell.

The virus manipulates the host cell's machinery to allow the virus to replicate and spread, they said.

The researchers found patterns of expression of the genes ACE2, which provide the genetic code for the SARS-CoV-2 receptor, and TMPRSS2, which provides the code for a molecule that cleaves both the viral spike protein and the ACE2 receptor, allowing infection to occur.

These genes were expressed during key stages of the embryo's development, and in parts of the embryo that go on to develop into tissues that interact with the maternal blood supply for nutrient exchange.

Gene expression requires that the DNA code is first copied into an RNA message, which then directs the synthesis of the encoded protein.

"Our work suggests that the human embryo could be susceptible to COVID-19 as early as the second week of pregnancy if the mother gets sick," said Professor Magdalena Zernicka-Goetz, who holds positions at both the University of Cambridge and Caltech.

"To know whether this really could happen, it now becomes very important to know whether the ACE2 and TMPRSS2 proteins are made and become correctly positioned at cell surfaces.

If these next steps are also taking place, it is possible that the virus could be transmitted from the mother and infect the embryo's cells," Zernicka-Goetz said.

Professor David Glover, also from Cambridge and Caltech, noted that genes encoding proteins that make cells susceptible to infection by the novel coronavirus become expressed very early on in the embryo's development.

"This is an important stage when the embryo attaches to the mother's womb and undertakes a major remodelling of all of its tissues and for the first time starts to grow," Glover said.

He added that COVID-19 could affect the ability of the embryo to properly implant into the womb or could have implications for future foetal health.

The team said that further research is required using stem cell models and in non-human primates to better understand the risk.

However, they said their findings emphasise the importance for women planning for a family to try to reduce their risk of infection.

Subscribe to newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

See the rest here:
Embryos could be vulnerable to covid-19 in second week of pregnancy: Study - Livemint

Read More...

Stromal Vascular Fraction Market 2019 to 2029 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast…

August 11th, 2020 12:50 pm

Stromal vascular fraction is gaining significant importance in various fields, including internal medicine, orthopaedics, plastic and general surgery,and wound healing.

Ease of harvest, abundant availability, and stable phenotype are some factors increasing the demand for stromal vascular fraction. Also, stromal vascular fraction secretes several soluble factors with anti-inflammatory, immunomodulatory, and analgesic effects, which leads to an alternative treatment option for various diseases, significantly benefitting the growth of thestromal vascular fraction marketduring the forecast period.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/20914

Company Profiles

Delivery of stromal vascular fraction by intra-articular injection has advantages over surgical implantation, such as less invasiveness, better patient compliance, and lower cost.

The global stromal vascular fraction market was valued atUS$ 76 Mnin 2018, and is expected to witness a CAGR of around4%over the forecast period (2019-2029).

Key Takeaways of Stromal Vascular Fraction Market Study

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/20914

Stromal vascular fraction has emerged as an efficient alternative in the field of regenerative medication. However, better-structured and significant clinical investigations need to be carried out to demonstrate and define the therapeutic potential of stromal vascular fraction,says a PMR analyst.

Stromal Vascular Fraction Manufacturers Focusing on Innovative Methods to Optimize Tissue Recovery

Consistent up-gradation and innovation in methods to recover adipose tissue-derived mesenchymal stem cells (ATD-MSCs) for autologous use in regenerative medication applications are expected to offer significant opportunities for the stromal vascular fraction market.

For instance, LipoCell from Tissyou, is furnished with a semipermeable film that separates fat tissues from squander components with the assistance of continuous irrigation. The dialysis of the tissue limits the pressure and trauma to the cell and extracellular matrix, evacuating the blood and oil deposits, which are pro-inflammatory.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/20914

More Valuable Insights on Stromal vascular fraction Market

Persistence Market Research brings a comprehensive research report on the forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029.

The global stromal vascular fraction market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provide compelling insights on the stromal vascular fraction market on basis of product (SVF isolation products, SVF aspirate purification products, and SVF transfer products), application (cosmetic applications, orthopedic applications, soft tissue applications, and others), and end user (hospitals, ambulatory surgical centers, stem cell laboratories, and others), across six major regions.

Continue reading here:
Stromal Vascular Fraction Market 2019 to 2029 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast...

Read More...

Landmark transplant in 1960s Virginia performed with heart stolen from a Black man – Live Science

August 11th, 2020 12:47 pm

On May 25, 1968, surgeons in Richmond, Virginia, performed a successful heart transplant, one of the world's first, on a white businessman. The heart that they used was taken from a Black patient named Bruce Tucker who had been brought to the hospital the day before, unconscious and with a fractured skull and traumatic brain injury. He was pronounced brain dead less than 24 hours later.

Tucker's still-beating heart was then removed without his family's knowledge or prior permission; their horrified discovery from the local funeral director that Tucker's heart was missing was a devastating blow.

The surgeons' actions, which led to America's first civil suit for wrongful death, are brought to light in the new book "The Organ Thieves: The Shocking Story of the First Heart Transplant in the Segregated South" (Simon and Schuster, 2020) by Pulitzer Prize-nominated journalist Charles "Chip" Jones. Jones raises troubling questions about the ethics of this pioneering transplant, revealing its deep roots in racism and discrimination toward Black people in health care.

Related: 7 Reasons America still needs civil rights movements

The first human organ transplant, a kidney, took place in 1954, and by the late 1960s, "superstar" surgeons were vying to be the first to successfully transplant a human heart, Jones told Live Science.

"In terms of science, it was the medical parallel to the space race," Jones said.

Dr. Richard Lower and Dr. David Hume, surgeons at the Medical College of Virginia (MCV) in Richmond, were at the forefront of that race, but it was South African surgeon Dr. Christiaan Barnard who performed the first heart transplant on Dec. 3, 1967. In May of 1968, MCV admitted to its hospital a patient with severe coronary disease who was a promising candidate for a heart transplant. But Lower and Hume had yet to find a viable heart donor.

And with time running out for their sick patient, they needed one fast.

Tucker, a Richmond factory worker who had sustained a serious head injury in a fall, was brought to the MCV Hospital on May 24, 1968. Though Tucker's personal effects included one of his brother's business cards, officials were unable to locate a family member on behalf of the unconscious man. And because the hospital claimed Tucker had no family and had liquor on his breath (he had been drinking prior to his accident), he was profiled as a "charity patient" and marked as a potential heart donor.

"He was in the wrong place at the wrong time," Jones said.

Tucker was connected to a ventilator, unable to breathe on his own. A junior medical examiner performed an electroencephalogram (EEG) to determine electrical activity in Tucker's brain; the examiner declared that there was none. The surgeons pronounced this to be sufficient evidence of brain death; Tucker was removed from the ventilator, and Hume and Lower removed Tucker's heart for the transplant, Jones wrote.

Related: What happens to your body when you're an organ donor?

Decades later, in 1981, the Uniform Determination of Death Act provided a legal definition of death: "irreversible cessation of circulatory and pulmonary functions" and "irreversible cessation of all functions of the whole brain," which means that the entire brain including the brain stem has ceased to function, according to Johns Hopkins Medicine.

But in 1968, the legal concept of death was not as clearly defined, Jones said.

"There was no statutory framework that would let doctors know how to proceed in a situation like this, where they had a patient that they legitimately thought had no chance of recovery," Jones explained. "And time was of the essence, in their view, to save a very sick man." However, the doctors were also quick to presume that Tucker was indigent and without family a racially motivated judgment, according to Jones.

Related: The 9 most interesting transplants

Tucker's family learned that his heart was missing from the funeral director; they pieced together what had happened from news reports (Tucker's identity was not initially released to the public, Jones wrote). Eventually, Tucker's family would file a civil lawsuit for wrongful death, which went to trial in 1972. Representing them was attorney L. Douglas Wilder, who later became the first elected Black governor in the U.S.

According to Wilder, Lower "willfully, wrongfully, wantonly and intentionally pronounced Bruce O. Tucker dead ahead of his actual death, in violation of the law, well knowing that he was not legally qualified to do so." State law required family notification and waiting for 24 hours before performing surgery.

"They skirted the process that was in place in Virginia because they were so eager to finally do the operation," Jones said.

The famous case of Henrietta Lacks presents a similar collision between medical ethics and racism. Lacks, a Black woman (also from Virginia), was diagnosed in 1951 with cervical cancer. A doctor collected cells from one of her tumors and then reproduced them indefinitely in the lab; after Lacks' death, those cells were then distributed widely among scientists for years without her family's knowledge or permission. Known as the HeLa cell line, they were used in research that led to cancer treatments and to the discovery of the polio vaccine, but decades passed before Lacks' family learned of her medical "immortality."

In 2013, the National Institutes of Health (NIH) reached an agreement with the family for permitting future research involving data from HeLa cells; the new process requires application through a panel that includes descendants and relatives of Lacks, Live Science previously reported.

The injustices experienced by Lacks, Tucker and their families stemmed from racism that is deeply embedded in America's medical infrastructure, Jones noted. In fact, when medical colleges in America adopted a more hands-on approach to anatomical studies during the 19th century, instructors frequently trained their students in human anatomy using cadavers of Black people that were stolen from African American cemeteries, Jones wrote.

Grave robbing was technically illegal, but when Black people were the victims, authorities tended to look the other way, according to Jones. Medical schools would hire a "body man" (also known as a "resurrectionist") to procure bodies; at MCV, the designated grave robber was a Black man named Chris Baker, a janitor at the school who lived in the basement of the college's Egyptian Building.

Most of the country's medical schools abandoned this racist method of procuring cadavers by the mid-1800s, but records suggest that it continued in Virginia until at least 1900, Jones said.

"There were news reports of bodies being 'snatched' from the Virginia state pen, which is about five blocks from the medical college," he said.

Jones unexpectedly discovered a reminder of this crime while researching his book, in a mural displayed in MCV's McGlothlin Medical Education Center. Painted between 1937 and 1947 by Richmond artist George Murrill, the mural celebrates the medical college's history. And it includes the image of a corpse being furtively carried away from a grave in a wheelbarrow.

"It shows how the legacy of racism is literally right under people's noses," Jones said.

"The Organ Thieves" is available to buy on Aug. 18; read an excerpt here .

Originally published on Live Science.

Read the rest here:
Landmark transplant in 1960s Virginia performed with heart stolen from a Black man - Live Science

Read More...

Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP – JD Supra

August 11th, 2020 12:47 pm

Chemotherapeutic drug resistance is one reason cancer remains an unsolved clinical problem despite the efforts ever since President Nixon declared his "War on Cancer" in 1971. Cancer cells, due in part to the genetic destabilization characteristic of the disease, are capable of expressing genes (normal or aberrant) that permit the cell to avoid the cytotoxic effect of such drugs with the patient providing the situs of selection for and growth of resistant cells. The phenomenon is certain tumor types can have more deleterious consequences than in others, and this is particularly true for glioblastomas (and their non-malignant counterparts, gliomas), cancer of the cells that protect neurons in brain. That organ, confined to the skull, cannot accommodate tumor growth without damaging the brain with which it is confined.

The chemotherapeutic drug of choice for treating glioblastomas is temezolomide (TMZ), an oral alkylating agent that had its chemotherapeutic effect by introducing alkyl groups onto nucleotide bases (preferably at the N-7 and O-6 positions of guanine and N-3 position of adenine) in tumor cell DNA preferentially (due to the greater amount of DNA synthesis occurring in these cells) and disrupting the process leading to cell death (the O-6 methylation having the greatest capacity to induce apoptosis or programmed cell death).O-6-methylguanosnine DNA methyltransferase (MGMT) is the cellular enzyme responsible for repairing alkylated bases in DNA and reduced expression of this gene (e.g., by hypermethylation of the MGMT promoter) is a biomarker for TMZ sensitivity in gliomas and glioblastomas. Recently, a multinational team of researchers* reported genetic rearrangements associated with TMZ resistance, in a paper entitled "MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas" published in Nature Communications. This paper shows a subset of gliomas with rearrangements in the MGMT gene that produce overexpression of the gene and resistance as a result. These authors screened 252 TMZ-treated recurrent gliomas by RNA sequencing and found eight different MGMT genetic fusions (designated BTRC-MGMT,CAPZB-MGMT,GLRX3-MGMT,NFYC-MGMT,RPH3A-MGMT, andSAR1A-MGMTin high-grade gliomas, HGG, andCTBP2-MGMTandFAM175B-MGMT in low-grade gliomas, LGG, in the paper) in seven patients (6 females) with recurrent disease, created by chromosomal rearrangement (see Figure 1c from paper; shown below). These individuals' tumors showed "significantly higher" expression of the rearranged MGMT gene product.

Upon further study, the authors report that five of the eight rearranged genes were located on Chromosome 10 in the vicinity of the MGMT gene itself. The breakpoint in the MGMT was uniformly found at the boundary of exon 2 of the MGMT gene, at a point 12 basepairs upstream of the ATG translation "start" codon. In three of the rearrangements, the breakpoint in the partner gene in the genetic fusion was found in the 5' untranslated region (UTR). All fusions were found to be in-frame (i.e., the reading frame of the MGMT transcript was not disrupted) and the functional regions of the MGMT protein (the methyltransferase domain and DNA-binding domain) were intact. A more fine-structure mapping experiment in the genetic rearrangement resulting in FAM175B-MGMTfound that the fusion was the consequence of a deletion of 4.8 Mb.

The effect of these rearrangements on MGMT expression was elucidated using CRIPSR-Cas9 to produce the BTRC-MGMT, NFYC-MGMT, SAR1A-MGMT, and CTBP2-MGMT rearrangements in cells of two glioblastoma cell lines, U251 and U87. When these cells and their untreated counterparts were challenged by growth in vitro with TMZ, only cells bearing the rearrangements (as confirmed by PCR analysis) were shown to be TMZ resistant. Unlike genetic rearrangements in other cancers that produce fusion proteins (such as the abl-bcr gene produced in chronic myelogenous leukemia bearing the diagnostic Philadelphia chromosome), because most of the rearrangements found involving the MGMT gene were located upstream of the initiation codon of the MGMT gene these authors reasoned that these rearrangements produce increased expression of MGMT leading to TMZ resistance because the cells were better able to repair the methylation injury and replicate functionally. This hypothesis was supported by real-time quantitative PCR analysis of MGMT transcripts in cells bearing the rearrangements, that showed a "striking" increase in expression of MGMT-encoding transcripts (an observation also found in tumors from patients whose gliomas or glioblastomas showed these rearrangements), and Western blot analysis confirmed higher expression levels of the MGMT protein. In two of the rearrangements (BTRC-MGMT and NFYC-MGMT), higher molecular weight fusion proteins were detected as predicted from the genetic data. These results were also replicated in patient tumor-derived stem cells for the BTRC-MGMTandSAR1A-MGMT rearrangements.

These results, and the researchers' conclusion that these rearrangements caused TMZ resistance by overexpression of MGMT, were confirmed by re-establishing TMZ sensitivity in these cells in the presence of O6-benzylguanine (O6-BG), an MGMT inhibitor. These results were further confirmed by detection of double-strand breaks in DNA in these cells in the presence of TMZ and O6-BG.

The relevance of these results to TMZ resistance in vivo was demonstrated using nude mouse xenograft models bearing tumors produced using BTRC-MGMT U251 cells and U251 cells without the rearrangement as control; these cells also contained a recombinant luciferase gene. Mice containing the rearrangement showed no significant prolongation of lifespan in the presence or absence of TMZ, indicating tumor cell resistance, whereas TMZ treatment of nave U251 cells showed improved survival.

While hypomethylation of the native MGMT promoter is the most frequently change associated with TMZ resistance, the results presented in this paper illustrate an alternative mechanism for glioblastomas and gliomas to acquire resistance to TMZ, the only current chemotherapeutic drugs for these maladies. Because these rearrangements were found in patients with recurrent tumors, these authors hypothesize that the rearrangements were selected or by TMZ treatment. A similar rearrangement has also been found in another cancer, medulloblastoma, after TMZ relapse. These authors also suggest that detection of these rearrangements can be used clinically to determine appropriate treatment modalities, particularly for recurrent disease.

* Seve Ballesteros Foundation Brain Tumor Group, Molecular Oncology Programme, Spanish National Cancer Research Center; Division of Life Science, Department of Chemical and Biological Engineering, Center of Systems Biology and Human Health and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology; Beijing Neurosurgical Institute, Capital Medical University; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Department of Systems Biology, Columbia University; The Jackson Laboratory for Genomic Medicine; and Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Center, CNIO, 28029, Madrid, Spain

Read the rest here:
Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra

Read More...

Trumps Unprecedented Attacks on Our Public-Health System – The New Yorker

August 11th, 2020 12:47 pm

How worried should we be that the President of the United States recently described as very impressive a woman who claims that doctors make medicine using DNA from aliens? Or that he shows no sign of recognizing the magnitude of the COVID-19 pandemic? Its simply not possible to worry too much.

I thought her voice was an important voice, Donald Trump said, after a reporter asked him why he would retweet the claims of Stella Immanuel, a Houston pediatrician with a long history of bizarre statements about medicine and human sexuality. Immanuel also shares Trumps unfounded enthusiasm for hydroxychloroquine. The drug has been repeatedly discredited as a treatment for this disease. She insists that it is a cure. Its tempting to write off this episode purely as evidence of Trumps disrespect for science. But the problem it represents is much bigger; it is the clearest sign yet that political interests and personal whims have eclipsed the rigor of some of our most important scientific institutions.

Twenty years ago, reporting from South Africa, I saw firsthand what happens when a national leader forces his people to subsist on lies and magic. From 2000 to 2005, according to a definitive study by researchers at the Harvard School of Public Health, Thabo Mbeki, then the President of South Africa, let as many as three hundred and thirty thousand of his fellow-citizens die and thirty-five thousand babies be born with H.I.V., by refusing to permit the countrys health service to treat AIDS with antiretroviral drugs. Mbeki and his health minister, Manto Tshabalala-Msimang, insisted that antiviral medicine was the product of a plot by Western pharmaceutical companies to kill Africans. The Harvard study concluded that the drugs were withheld largely because of Mbekis well-known refusal to initially accept that AIDS is caused by a virus, H.I.V.

No single national leader would have been able to prevent the coronavirus pandemic. But Trumps denialism and hostility toward public-health officials has greatly increased Americas share of suffering and death. On Fox & Friends, on Wednesday, he said that the virus is spreading in a relatively small portion of the country, and that children are virtually immune; both statements are false. And, as he has done many times before, he declared at a briefing that the pandemic would just go away.

Trump has had one consistent response to the pandemic: he attacks leading experts when they attempt to tell the truth. Last week, when Deborah Birx, the cordinator of the White House coronavirus task force, characterized the epidemic as extraordinarily widespread, Trump tweeted that she was pathetic. Earlier this year, when Anthony Fauci, the nations leading infectious-disease expert, was asked at a briefing to discuss his view on hydroxychloroquine, Trump prevented him from answering. The Presidents refusal either to lead or to recognize the leadership of others has made it impossible to develop a national plan to combat this virus.

Without such a plan, the nation has been subjected to a giant game of viral roulette. With no coherent system of rapid tests, contact tracing is all but useless. Since we have neither a vaccine nor any general therapy, tests and tracing offer the only near-term hope of controlling the pandemic. States have largely been left to fend for themselves. Last week, seven governors, Republicans and Democrats, formed their own testing coalition.

On Wednesday, Fauci was asked if the United States had the worlds worst COVID-19 outbreak. It is quantitatively, if you look at it, he said. I mean, the numbers dont lie. Trump is asked similar questions nearly every day. And, although the numbers may not lie, the President does. As he put it in a recent tweet, You will never hear this on the Fake News concerning the China Virus, but by comparison to most other countries, who are suffering greatly, we are doing very well. No amount of statistical massaging could make that statement true.

This war on reality has deeply wounded Americas public-health system. In March, under relentless pressure from Trump and his trade adviser, Peter Navarro (who has no medical training), the Food and Drug Administration issued an emergency-use authorization (E.U.A.) for hydroxychloroquine. That allowed doctors to administer the drug to patients who were severely ill, but it was not an approval of the drug for general use. As Janet Woodcock, who runs the F.D.A.s Center for Drug Evaluation and Research, put it in an interview with Stat, We simply said its possible from the in vitro data this may have a beneficial effect and the benefits may outweigh the risks. Few people understood that distinction, and, goaded on by the President, few listened to those who urged caution.

Trump announced on national television that hydroxychloroquine could be a game changer. It wasnt. Former F.D.A. officials were astonished by the rushed action. I understand the desire to find hope, but we need more evidence than is currently available before we encourage widespread use, Margaret A. Hamburg said at the time. She served as the F.D.A. commissioner for six years under Barack Obama.

In June, when the drugs ineffectiveness had become apparent, the F.D.A. revoked the E.U.A. It was a remarkable retreat. While it is reassuring that the agency finally made a decision based on data, the drug should not have been released for this use in the first place. But, when politics takes precedence, facts no longer matter. Rick A. Bright, one of the nations experts on pandemic preparedness and the chief of BARDA (the Biomedical Advanced Research and Development Authority), had objected to the use of the drug and tried to stop it. He was fired. As the Times reported on Monday, Stephen Hahn, the current F.D.A. commissioner, is not allowed to speak to the press unless Michael Caputo, an assistant secretary of the Department of Health and Human Services, or another official, is also on the line. Caputo has long been associated with Trump, once serving as his driver.

We have recently witnessed an even more pernicious example of an American scientific colossus bowing to Trumps ignorance. In May, the Centers for Disease Control and Prevention issued stringent guidelines to determine when and if schools should reopen this fall. Trump has insisted, against all scientific advice, that all schools should open. He tweeted, I disagree with the @CDCgov on their very tough & expensive guidelines for opening schools. While they want them open, they are asking schools to do very impractical things. I will be meeting with them!!!

Robert Redfield, the director of the C.D.C., immediately issued an update to the guidelines, announcing that it is critically important for our public health to open schools this fall. The reversal was stunning; past C.D.C. directors were not immune to politics, and they understood that a President might overrule them. But there has always been an understanding at the agency that all public-health decisions made there would have to be governed by data.

No agency or scientist is infallible. Early in the pandemic, the C.D.C. failed to introduce accurate test kits; many of the kits it distributed were contaminated and useless. The agency used highly sensitive tests based on PCR technology, which is a kind of molecular copying machine that makes millions (or billions) of copies of a DNA sample. That makes it much easier for clinicians to detect any specific sequence of DNA, including those in the coronavirus. The technology has been used routinely for more than three decades, but it is sensitive to small errors, and there were several in the C.D.C. kits. The misstep delayed accurate data collection throughout the United States at one of the most critical moments in the pandemic.

See the original post here:
Trumps Unprecedented Attacks on Our Public-Health System - The New Yorker

Read More...

Are very long-lived trees immortal and what can they teach humans? – ABC News

August 11th, 2020 12:47 pm

While humans are all too familiar with the ravages of getting older, many trees seem to handle ageing a lot better.

Certain trees can live for thousands of years and appear to be immortal.

But not everyone is convinced these old timers can escape death due to old age.

Regardless, could humans with their relatively puny lifespans have something to learn from these ancient trees? Some scientists think so.

Establishing how old the oldest living tree is depends a bit on which plants are in the running for the title.

You could argue that Australia's Wollemi pine, which has been cloning itself for more than 60 million years, deserves the title. But that's kind of cheating because this involves multiple stems growing from the one rootstock.

This is why the oldest tree in the world is generally regarded as a single-stemmed bristlecone pine called Pinus longaeva.

This species can live to around 5,000 years and does well where most other plants cannot even grow in rocky, dry, high-altitude areas in the United States.

What's amazing is that scientists have not so far been able to show that getting older directly affects the health of such millennial trees, plant biologist Sergi Munne-Bosch from the University of Barcelona says.

It's because of this, some have suggested these trees are essentially immortal.

But in a recent article, Professor Munne-Bosch argues that it's likely even ancient trees could die from old age assuming something else doesn't kill them first.

He emphasises that there's a difference between ageing, which is about how long an organism has lived, and age-related deterioration, which is referred to as senescence.

"Just because we can't track senescence in long-lived trees doesn't mean they are immortal."

Professor Munne-Bosch points to recent research on centuries-old Ginkgo biloba trees that found no evidence of senescence.

The study was the first to look for evidence of age-related changes in cells of the cambium, a layer just beneath the bark that contains cells that can produce new tissue throughout the plant's life.

It confirmed the long-lived trees, which in this case were up to 667 years old, were just as healthy as younger ones says Professor Munne-Bosch.

"They grow very well, they produce seeds, they produce flowers, so they are healthy."

He points out that even though a 667-year-old tree seems old when compared to a human, it is relatively young for a ginkgo.

"This species can live for more than two millennia."

Professor Munne-Bosch argues that the ginkgo researchers' data shows that older trees had thinner vascular tissue and that this hints at possible age-related deterioration that would be more obvious in even older trees.

Yet despite this deterioration, he says these trees are more likely to die from insects, disease, fire, drought or loggers, than old age.

"For a species that can live for millennia, aging is not really a problem in evolutionary terms because they are much more likely to die of something else."

The problem is there are so few of these long-lived trees that it's hard to get the data to know for certain whether they can die of old age.

"We cannot prove it either way," Professor Munne-Bosch says, adding that age-related deterioration is likely to happen in these trees at such a different pace compared to in humans.

"For a Ginkgo biloba, six centuries is not as physiologically relevant as it is to us."

Brenda Casper, a professor of biology at the University of Pennsylvania says it's not clear that the changes found in the older Ginkgo biloba trees were necessarily detrimental to the tree.

But she agrees the low number of millennial trees makes it hard to study their longevity.

"It's difficult to find statistical evidence for senescence."

Even if there were enough trees, she says some of the age-related deterioration may be hard to detect, or we may not know what to look for.

"It's not just internal physiology per se but it's the interaction of the tree with its environment."

For example, she says it would be hard to measure whether age had made a tree more susceptible to disease, or less structurally sound so it's more likely to fall over in a windstorm.

Even if the jury is out on whether millennial trees are immortal, some experts say their longevity could be inspirational for medical research.

Professor Munne-Bosch says such trees can draw on a bag of tricks to help them "postpone death".

First is having a simple body plan with modular-like branches and roots. This means they can compartmentalise any damaged or dead roots or branches and work around them.

"They can lose part of leaves or roots and continue to be healthy..

And he says although 95 per cent of the trunk of a tree might be dead, the living cambium just beneath the bark is "one of the secrets of longevity" in trees.

Millennial trees have used the combination of these features to their best advantage and Professor Munne-Bosch says these tricks are providing a model for scientists researching the negative effects of ageing.

"Imagine if we could regenerate our lungs or circulatory system every year, we would be much healthier than we are."

Want more science plus health, environment, tech and more? Subscribe to our channel.

Professor of biomedical engineering at the University of New South Wales, Melissa Knothe Tate is one researcher who is inspired by millennial trees.

"They have units and if one unit breaks you can replace it with another unit."

Only a small percentage of an individual long-lived tree may be alive, but she argues it's all about survival of the cells that are able to regenerate the tree.

"Those that survive best, survive longest."

"Millennial trees are the best survivors because they've seen a lot."

While a tree and a human might seem worlds apart, Professor Knothe Tate sees the similarities, pointing to the role of stem cells in maintaining bones in humans.

She says cells add new layers to bone, like tree rings, to increase girth and when bone is injured, stem cells quickly help repair it.

"We're constantly renewing our bones and trees do something similar."

Professor Knothe Tate says she is using stem cells and new biomaterials that emulate tree cambium, to create replacement tissue in the lab, and has several patents for the work.

"I think about plants a lot when I'm up in the mountains and amongst the trees."

Professor Knothe Tate, who draws on her training in philosophy, biology and mechanical engineering for her work, sees other similarities that can inspire research.

For example, she likens the human brain to the network of roots and branches that helps a tree remain resilient if one part is damaged, another part can sometimes take up the slack.

"As parts of the brain are injured or die, it's remarkable what functionality we can retain,

"If we knew which of the brain's networks were essential for certain functions, we may be able to grow them."

Want even more science, health and tech? Join the conversation on Facebook.

Professor Knothe Tate also set up a science education project for girls that explores the parallels between the biomechanics of trees and bones. It was inspired by her observation of how huge trees sway like a blade of grass in the wind.

She has high hopes for the potential of regenerative medicine research that draws on knowledge from other disciplines like plant biology to extend human life.

"We can then start to think about making ourselves immortal."

Plant biologist Professor Munne-Bosch is also enthusiastic.

"The future of medicine is very similar to what has evolved in millennial trees."

But while regenerating tissues will help humans live much longer, he doubts we will ever be immortal.

"It won't be forever, because we are more likely to die of something else, whether it be an accident or a pandemic."

Get all the latest science stories from across the ABC.

Read this article:
Are very long-lived trees immortal and what can they teach humans? - ABC News

Read More...

#LoveYourAgeChallenge: Join cancer Ambassador of Hope in this fund-raiser – Brakpan Herald

August 11th, 2020 12:47 pm

It is a widely known fact that cancer is one of the major diseases causing death throughout both the developed and developing world, including South Africa.

Approximately 115 000 South Africans are diagnosed with cancer each year, and with a 6/10 survival rate it is easy to understand how news of such a diagnosis can fuel fear and anxiety for individuals and their families.

Against this background, one can easily understand why the need for hope from various sources becomes the lifeline for families dealing with cancer.When one thinks of the words hope, determination and inspiration, Richard Wright, when you meet him, embodies the meaning of these three words.

Having survived brain cancer three times, Richard has first-hand experience of how important holding on to hope fuelled his ability to stay emotionally strong when the disease weakened his body.

I didnt think Id see the age of 50, and am acutely aware of the gift ones age represents, said Richard.

As a result of his journey, Richard became acquainted with The Sunflower Fund and has become an inspiration to the staff as well as supporters of the cause at events in the past.

As part of my 50th birthday celebration, I am encouraging the public to take part in my #LoveYourAgeChallenge, in hopes of raising funds for The Sunflower Fund to assist patients who suffer from life-threatening blood disorders, continued Richard.

Join Richard in celebrating his age by celebrating your age. The challenge encourages individuals to create an activity of their choice, whether it is a 50-minute hike, baking 50 cakes or 50 minutes of meditation, making it relative to your age. Post your event selfie or video using the hashtag #LoveYourAgeChallenge and you could win great prizes.

Richard encouraged participants to spread the love by donating any amount to The Sunflower Fund to give hope. Any amount, no matter how big or small to reflect your age R5, R50 or R50 000.

The Sunflower Fund is a stem cell donor recruitment centre and registry that fights blood diseases by helping patients in need of a transplant find their life-saving matching donor. When a patient needs a transplant, the donor needs to be a DNA or genetic match, which is not as simple as matching a blood type. Patients have a 25 per cent chance of this match existing within the family. The remaining 75 per cent chance is based on finding a match from a database of strangers who have signed up to save a life should they match a patient.

An added factor is that the likelihood of this match most often exists within the same ethnic and cultural mix as the patient. As such, The Sunflower Fund is committed to building an ethnically diverse registry of donors, to give patients the best hope of a cure.

Our ambassador of hope programme is one of the key ways we work with people from various walks of life to help us raise awareness about the urgent need for blood stem cell donors, said Alana James, CEO of The Sunflower Fund. This awareness is vital to increasing the number of registered donors and we are pleased to have Richard on board as an Ambassador of Hope.

Richard is a husband, father, motivational speaker and advocate for determination and strength. He is a storyteller, skilled at using his experiences to inspire and transform the thinking of his audiences.

I also want to encourage individuals to be the hope by becoming stem cell donors. People have the power to change their mindset from just cancer awareness to being a part of the solution. As I always say mindset matters, added Richard.

Individuals between the ages of 18 and 55 can register as donors. If you have a consistent body weight of more than 50kgs and a BMI of less than 40, you could be eligible to be a donor.

For additional information on The Sunflower Fund, or to become a donor, visit https://www.sunflowerfund.org/

Have a story?

Contact the newsroom by emailing:Thelma Koorts (editor)[emailprotected]

orStacy Slatter (news editor)[emailprotected]

or Min Fourie(journalist)[emailprotected]

Remember to visit theBrakpan Heraldon the following social media platforms:

Follow us:

Read this article:
#LoveYourAgeChallenge: Join cancer Ambassador of Hope in this fund-raiser - Brakpan Herald

Read More...

Page 456«..1020..455456457458..470480..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick